What a 1 mL syringe does that a 0.3 mL syringe does not

There is a detail on the barrel that causes more trouble than the convention itself. Small insulin syringes — the 0.3 mL and 0.5 mL barrels — are generally marked in single-unit increments, and some 0.3 mL barrels in half units. The 1 mL barrel is very often marked in two-unit increments, because a hundred single marks will not fit legibly. A person who learns to count marks on one barrel and then buys another size will count the same marks and administer twice or half what they intend. We have seen this reported repeatedly, and it is invisible unless somebody looks at the printing.

The hundred-unit convention

An insulin syringe is graduated in units on a convention that fixes one hundred units to one millilitre. A unit is therefore ten microlitres of liquid. That is the entire definition and it contains no information about drug content.

The convention works for insulin because insulin is supplied at a standardised strength: U-100 insulin contains one hundred international units of insulin activity per millilitre, so one syringe unit delivers one insulin unit. The volumetric mark and the dose mark coincide, which is why generations of patients have been able to dose by counting marks without ever thinking about volume.

Take the same syringe and use it for a peptide reconstituted at a concentration of the user’s choosing and the coincidence breaks. The syringe is still an accurate volumetric instrument; it is simply no longer a dosing instrument. Everything a person needs in order to convert marks into micrograms depends on a calculation somebody has to perform.

The Journal labours this because it is the root of the largest errors in this market. A reader who takes away only one sentence should take away this one: the unit tells you the volume, and only the concentration tells you the dose.

Barrel size and graduation interval

U-100 insulin syringes are commonly supplied in three barrel sizes. The 0.3 mL barrel holds thirty units and is usually graduated in single units, with some products marked in half units. The 0.5 mL barrel holds fifty units and is generally marked in single units. The 1 mL barrel holds one hundred units and is very often marked in two-unit increments, because a hundred legible single marks will not fit on a barrel of that length.

The practical consequence is direct. A person accustomed to counting single marks on a 0.5 mL barrel who switches to a 1 mL barrel and counts the same number of marks will draw twice the intended volume. The reverse switch halves it. Nothing about the appearance of the syringe warns of this; only the printed numerals do, and they are small.

The general rule that follows is to choose the smallest barrel that comfortably holds the intended volume, both for graduation resolution and because a small volume measured near the bottom of a large barrel is the least accurate configuration available. Where a dose is genuinely small — a few units — a half-unit-graduated 0.3 mL barrel is the only presentation that offers meaningful resolution.

Reading a barrel accurately

Three reading errors recur. The first is counting marks rather than reading numerals, which fails at the first change of barrel size. The second is reading to the wrong part of the plunger: the measurement is taken at the leading edge of the rubber stopper, not the tip of any conical projection beyond it, and on some designs the difference is a full unit. The third is parallax, which sounds fussy and is not: at small volumes, viewing the barrel from above or below the mark introduces a readable error.

The remedy for all three is the same and takes seconds. Read the numeral, not the count. Hold the barrel at eye level. Identify the leading edge of the stopper before drawing rather than after.

There is a further consideration specific to this market. Syringes sold for general medical use — tuberculin syringes, for instance — are graduated in millilitres and fractions of a millilitre. They are the same size and shape as insulin syringes, and in the same drawer. Using them requires reading a completely different scale, and the failure to notice the substitution is the single commonest route to a tenfold error that we have documented.

Dead space, air and the dose that stays behind

Dead space is the volume held in the needle and hub after the plunger has bottomed out. For a fixed-needle insulin syringe it is very small, of the order of two to seven microlitres. For a detachable needle on a conventional luer fitting it is considerably larger, sometimes exceeding fifty microlitres.

Whether that matters is a question of proportion. At an intended volume of two hundred microlitres, a five-microlitre loss is under three per cent and irrelevant. At an intended volume of twenty microlitres — which a concentrated reconstitution produces — the same loss is a quarter of the dose. This is one of the strongest practical arguments against making a vial up to a very high concentration: it pushes the injection volume down into the range where fixed losses dominate.

Air bubbles interact with the same arithmetic. A bubble displaces solution, so a barrel drawn to eight units containing a one-unit bubble delivers seven units of drug. Small bubbles in a subcutaneous injection are not a safety problem in the way they would be intravenously; they are a dosing problem. Expelling them by tapping the barrel upright and pushing the plunger to the mark is a volumetric correction, not a ritual, and it matters most at exactly the small volumes where people are least inclined to bother.

The arithmetic is only as good as the label

Every calculation above starts from a stated mass of peptide in the vial. For licensed product that figure is a release specification. For research-grade lyophilised powder it is a claim, and the difference matters because the claim sits at the front of every subsequent computation.

Two distinct quantities are involved. Chromatographic purity is the proportion of peptide-related material that is the intended peptide. Peptide content is the fraction of the vial mass that is peptide at all, the remainder being counter-ions, residual solvent, water and excipient. A vial can be ninety-nine per cent pure and contain materially less peptide than labelled, and content is the number that determines a dose.

The four independent services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — report purity routinely and content less consistently. Several vendors, among them WXT, SSA, CPC, SWB and MKM, publish per-batch reports; others publish nothing verifiable. Where content has not been measured, the labelled mass should be treated as an upper bound and the resulting dose figure as an estimate. That is unsatisfying and it is honest, and it is why the Journal has argued in Analytics for content and endotoxin as standard reported fields.

How the Journal reports technique

Two bodies of evidence underlie this file. Questions of tissue, depth, needle length and rotation come from the insulin injection-technique literature, which is large, well conducted and directly transferable because it concerns anatomy rather than any particular molecule. Questions of absorption by site, in-use stability and exposure come from the incretin literature, which is smaller and where we say so. Where we describe practice rather than evidence, the text states it.

We give arithmetic in full rather than in tables of pre-computed unit counts, deliberately. A pre-computed table is correct only for the concentration it was computed for, and the recurring error in this market is precisely the reuse of a correct number under changed conditions. A reader who can perform the four-line calculation is protected against a class of error that no table can prevent.

Nothing in this file is medical advice. The Journal does not recommend doses, products, diluents or suppliers, and cannot assess an individual. Several compounds discussed are sold for research use only, are not approved for human use in any jurisdiction, and are not manufactured or released to any human sterility, content or endotoxin standard. Injection technique is properly taught in person by a clinician or nurse, and this file is not a substitute for that.

A short glossary

Unit (U-100): ten microlitres. A volume, not an amount of drug. Concentration: mass per volume, here usually milligrams per millilitre. Dead space: volume retained in needle and hub after full depression of the plunger. Priming: expelling a small volume before dosing, to clear air and confirm flow.

Gauge: needle bore, inversely numbered — higher gauge is thinner. Subcutaneous: into the fat layer beneath the dermis. Intradermal: within the skin itself, which is what an oblique short needle risks. Intramuscular: into muscle beneath the subcutaneous layer.

Lipohypertrophy: thickened subcutaneous tissue from repeated injection, with blunted and variable absorption. Lipoatrophy: localised loss of subcutaneous fat, a different and now rare immune-mediated phenomenon. Bacteriostatic: inhibiting microbial growth, not sterilising. In-use period: the interval after first puncture during which a product remains within specification, established by stability testing.

The distinction between bacteriostatic and sterile, and the distinction between purity and content, account between them for a large share of the confused correspondence this desk receives.

One thing we would like to see changed is trivially achievable. Needles are cheap, and reuse is driven almost entirely by cost and availability rather than by any belief that it is safe. Of every technique failure catalogued above, that is the one most responsive to supply, and the one where the barrier is commercial rather than educational.